TIGIT Inhibitors Infographic
TIGIT Inhibitors Infographic

TIGIT Inhibitors Overview:

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is one of the most recent immune checkpoints to be investigated as an immunotherapeutic target. TIGIT is a transmembrane glycoprotein receptor with an Ig-like V-type domain and an ITIM in its cytoplasmic domain.

TIGIT Inhibitors Therapies: 20+

TIGIT Inhibitors Companies: 18+ 

Key TIGIT Inhibitors Companies

  • Merck Sharp & Dohme
  • Bristol-Myers Squibb
  • BeiGene
  • Arcus Biosciences
  • iTeos Therapeutics
  • Mereo BioPharma
  • Phio Pharmaceuticals
  • Bio-Thera Solutions
  • Compugen
  • And several others.

TIGIT Inhibitors Report Assessment

  • Company Analysis
  • Therapeutic Assessment
  • Approved/Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Therapeutic Assessment:

  • By Product Type
  • By Stage and Product Type
  • By Route of Administration
  • By Stage and Route of Administration
  • By Molecule Type
  • By Stage and Molecule Type

Related Reports:

TIGIT Inhibitors - Pipeline Insight, 2022